SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...
Hence then, the article about ark biopharmaceutical receives china marketing authorization for aizhida for the treatment of adhd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD )
Also on site :
- 1960s Rock Anthem, Inspired by Old Supernatural Horror, Became An Anti-War Anthem
- TSA Sends Warning to World Cup Fans Visiting Texas
- Amazon’s 'Elegant' 3-Piece Rattan Patio Set Is a Coastal Summer Upgrade That's Now Just $75 for Prime Day